mRNA-1273
Showing 1 - 25 of 838
COVID-19, COVID-19 Immunisation Trial in Decatur, Bethesda, Seattle (mRNA-1273)
Completed
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
-
Decatur, Georgia
- +2 more
Jan 26, 2023
SARS-CoV-2 Trial in United States (mRNA-1273.211, mRNA-1273, mRNA-1273.617.2)
Active, not recruiting
- SARS-CoV-2
- mRNA-1273.211
- +6 more
-
Sacramento, California
- +22 more
Nov 16, 2022
Lung Transplant Recipient, SARS-CoV-2, Immunosuppression Trial (mRNA-1273 (Moderna COVID-19 vaccine))
Active, not recruiting
- Lung Transplant Recipient
- +2 more
- mRNA-1273 (Moderna COVID-19 vaccine)
-
Los Angeles, CaliforniaUCLA Clinical Translational Research Center
Dec 13, 2022
COVID-19 Immunogenicity ofThird Dose of mRNA-1273 Vaccine Among
Active, not recruiting
- Covid19
- SARS-CoV2 Infection
- mRNA-1273
-
Tampa, FloridaMoffitt Cancer Center
Jun 20, 2022
Healthy, Chronic Stable Illness Trial in United States (casirivimab+imdevimab, Moderna mRNA-1273 vaccine)
Completed
- Healthy
- Chronic Stable Illness
- casirivimab+imdevimab
- Moderna mRNA-1273 vaccine
-
Little Rock, Arkansas
- +5 more
Jan 9, 2023
Solid Tumor Malignancy, Hematologic Malignancy, Leukemia Trial run by the NCI (mrna 1273 injection)
Recruiting
- Solid Tumor Malignancy
- +4 more
- mRNA-1273
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 14, 2023
SARS-CoV-2 Trial in United States (mRNA-1283, mRNA-1273, Placebo)
Active, not recruiting
- SARS-CoV-2
- mRNA-1283
- +2 more
-
Chandler, Arizona
- +4 more
Sep 22, 2022
COVID-19, COVID-19 Immunisation Trial in United States (mRNA-1273, mRNA-1273.351)
Active, not recruiting
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
- mRNA-1273.351
-
Decatur, Georgia
- +3 more
Aug 11, 2022
Healthy Adult Volunteers Trial in Taipei City (ChAdOx1-nCov-19 (Astra-Zeneca), SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine)
Completed
- Healthy Adult Volunteers
- ChAdOx1-nCov-19 (Astra-Zeneca)
- SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine
-
Taipei City, X, TaiwanNational Taiwan University Hospital
Oct 16, 2022
SARS-CoV-2 mRNA-1273 Vaccine in Select Subsets of Oncology
Active, not recruiting
- Covid19
- Cancer
- Blood Sample
-
Rochester, New YorkUniversity of Rochester
Sep 6, 2022
SARS-CoV-2, Influenza Trial in United States (mRNA-1073, mRNA-1010, mRNA-1273)
Active, not recruiting
- SARS-CoV-2
- Influenza
- mRNA-1073
- +3 more
-
Hollywood, Florida
- +13 more
Oct 5, 2022
Risk Factors of Myocarditis and Pericarditis After Moderna
Active, not recruiting
- Myocarditis, Pericarditis
- mRNA-1273
-
Aarhus, Denmark
- +4 more
Oct 31, 2023
Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among
Completed
- SARS-CoV-2
-
New York, New YorkAetion Inc.
May 5, 2022
SARS-CoV-2 Trial in United States (mRNA-1273.214)
Recruiting
- SARS-CoV-2
- mRNA-1273.214
-
Montebello, California
- +6 more
Jul 28, 2022
COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection Trial in Ramat-Gan (mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo)
Recruiting
- COVID-19 Pandemic
- +3 more
- mRNA-1273.214 Vaccine
- +2 more
-
Ramat-Gan, IsraelSheba Medical Center
Oct 26, 2022
COVID-19 Trial in Melbourne (Tozinameran, Elasomeran, Bivalent Pfizer-BioNTech)
Not yet recruiting
- COVID-19
- Tozinameran
- +3 more
-
Melbourne, Victoria, AustraliaRoyal Children's Hospital, Murdoch Children's Research Institute
Sep 14, 2022
COVID-19 Pandemic Trial in Ramat-Gan (mRNA1273 vaccine)
Active, not recruiting
- COVID-19 Pandemic
- mRNA1273 vaccine
-
Ramat-Gan, IsraelSheba Medical Center
Feb 8, 2022
SARS-CoV-2 Trial in Atlanta, Seattle (mRNA-1273)
Active, not recruiting
- SARS-CoV-2
- mRNA-1273
-
Mesa, Arizona
- +14 more
Aug 31, 2022
Severe Exacerbation of Severe Acute Respiratory Syndrome
Active, not recruiting
- SARS-CoV-2
-
Tokyo, JapanCMIC Co. Ltd.,
Jun 5, 2023
Infectious Disease, COVID-19 Trial (RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg)
Recruiting
- Infectious Disease
- COVID-19
- RVM-V001 10 µg
- +2 more
-
Brookvale, New South Wales, Australia
- +1 more
Sep 12, 2022
A Study of the Effectiveness of Moderna COVID-19 Vaccine
Recruiting
- SARS-CoV-2
- COVID-19
- mRNA-1273
-
Pasadena, CaliforniaKaiser Permanente Southern California
Jul 5, 2023
Japan After Severe Acute Respiratory Syndrome Coronavirus 2
Not yet recruiting
- SARS-CoV-2
-
Tokyo, JapanCMIC Co., Ltd
Jun 6, 2023
COVID-19 Trial in Vienna (Ad26COVS1, ChAdOx1 SARS2 Vaccine, BNT162B2)
Active, not recruiting
- COVID-19
- Ad26COVS1
- +3 more
-
Vienna, AustriaMedicial University of Vienna
Apr 12, 2022
COVID-19 Vaccine Trial in Kaohsiung, Taipei (Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222)
Recruiting
- COVID-19 Vaccine
- Half dose of MVC-COV1901
- +3 more
-
Kaohsiung, Taiwan
- +3 more
Mar 28, 2022
COVID-19, Breakthrough Infection Trial in Taoyuan city (BNT162b2, mRNA-1273, MVC-COV1901)
Active, not recruiting
- COVID-19
- Breakthrough Infection
- BNT162b2
- +2 more
-
Taoyuan city, TaiwanChang Gung Memorial Hospital
Jul 21, 2022